Brokerages forecast that Medidata Solutions Inc (NASDAQ:MDSO) will report $0.36 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Medidata Solutions’ earnings, with the lowest EPS estimate coming in at $0.32 and the highest estimate coming in at $0.39. Medidata Solutions reported earnings of $0.33 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 9.1%. The business is expected to issue its next earnings report on Thursday, October 25th.

On average, analysts expect that Medidata Solutions will report full year earnings of $1.57 per share for the current fiscal year, with EPS estimates ranging from $1.50 to $1.65. For the next year, analysts expect that the company will post earnings of $1.93 per share, with EPS estimates ranging from $1.71 to $2.10. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Medidata Solutions.

Medidata Solutions (NASDAQ:MDSO) last announced its earnings results on Tuesday, July 24th. The company reported $0.43 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.39 by $0.04. The firm had revenue of $155.90 million during the quarter, compared to analyst estimates of $155.86 million. Medidata Solutions had a net margin of 9.13% and a return on equity of 11.37%. The company’s revenue for the quarter was up 14.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.31 EPS.

A number of brokerages recently weighed in on MDSO. BidaskClub lowered shares of Medidata Solutions from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 26th. Zacks Investment Research lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Thursday, June 21st. First Analysis began coverage on shares of Medidata Solutions in a research note on Thursday, June 14th. They issued an “equal weight” rating and a $86.00 target price for the company. Royal Bank of Canada reduced their target price on shares of Medidata Solutions to $91.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, ValuEngine raised shares of Medidata Solutions from a “hold” rating to a “buy” rating in a research note on Monday, July 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $87.17.

NASDAQ MDSO traded down $0.26 on Tuesday, reaching $73.06. The company had a trading volume of 919,900 shares, compared to its average volume of 623,903. The firm has a market cap of $4.42 billion, a PE ratio of 85.96, a PEG ratio of 4.64 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.16. Medidata Solutions has a 1-year low of $59.60 and a 1-year high of $88.87.

In other Medidata Solutions news, Director Lee Shapiro sold 12,500 shares of the business’s stock in a transaction dated Thursday, July 26th. The shares were sold at an average price of $76.16, for a total transaction of $952,000.00. Following the sale, the director now directly owns 26,028 shares of the company’s stock, valued at approximately $1,982,292.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Taylor sold 5,000 shares of the business’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $73.05, for a total transaction of $365,250.00. Following the sale, the director now directly owns 44,036 shares in the company, valued at $3,216,829.80. The disclosure for this sale can be found here. Insiders have sold a total of 29,788 shares of company stock worth $2,325,937 over the last three months. Insiders own 4.70% of the company’s stock.

A number of large investors have recently modified their holdings of the business. Janus Henderson Group PLC raised its holdings in shares of Medidata Solutions by 69.7% in the 2nd quarter. Janus Henderson Group PLC now owns 1,904,094 shares of the company’s stock valued at $153,394,000 after purchasing an additional 782,194 shares during the period. Fred Alger Management Inc. raised its holdings in shares of Medidata Solutions by 87.3% in the 2nd quarter. Fred Alger Management Inc. now owns 1,068,170 shares of the company’s stock valued at $86,052,000 after purchasing an additional 497,817 shares during the period. Echo Street Capital Management LLC bought a new stake in shares of Medidata Solutions in the 1st quarter valued at about $26,495,000. Rockefeller Capital Management L.P. bought a new stake in shares of Medidata Solutions in the 1st quarter valued at about $24,168,000. Finally, Ownership Capital B.V. bought a new stake in shares of Medidata Solutions in the 2nd quarter valued at about $29,140,000.

Medidata Solutions Company Profile

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Further Reading: Discover Your Risk Tolerance

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.